N-acetylcysteine inhibits endothelial cell invasion and angiogenesis

Tania Cai, GianFranco Fassina, Monica Morini, Maria Grazia Aluigi, Luciana Masiello, Gabriella Fontanini, Francesco D'Agostini, Silvio De Flora, Douglas M. Noonan, Adriana Albini

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

The thiol N-acetylcysteine (NAC) is a chemopreventive agent that acts through a variety of mechanisms and can prevent in vivo carcinogenesis. We have previously shown that NAC inhibits invasion and metastasis of malignant cells as well as tumor take. Neovascularization is critical for tumor mass expansion and metastasis formation. We investigated whether a target of the anti-cancer activity of NAC could be the inhibition of the tumor angiogenesis-associated phenotype in vitro and in vivo using the potent angiogenic mixture of Kaposi's sarcoma cell products as a stimulus. Two endothelial (EAhy926 and human umbilical vein endothelial [HUVE]) cell lines were utilized in a panel of assays to test NAC ability in inhibiting chemotaxis, invasion, and gelatinolytic activity in vitro. NAC treatment of EAhy926 and HUVE cells in vitro dose-dependently reduced their ability to invade a reconstituted basement membrane, an indicator of endothelial cell activation. Invasion of HUVE cells was inhibited with an ID50 of 0.24 mM NAC, whereas inhibition of chemotaxis required a 10 fold higher doses, indicating that invasion is a preferential target. NAC inhibited the enzymatic activity and conversion to active forms of the gelatinase produced by endothelial cells. The matrigel in vivo assay was used for the evaluation of angiogenesis; NAC strongly inhibited neovascularization of the matrigel sponges in response to Kaposi's sarcoma cell products. NAC prevented angiogenesis while preserving endothelial cells, implying that it could be safely used as an anti-angiogenic treatment.

Original languageEnglish
Pages (from-to)1151-1159
Number of pages9
JournalLaboratory Investigation
Volume79
Issue number9
Publication statusPublished - Sep 1999

Fingerprint

Acetylcysteine
Endothelial Cells
Human Umbilical Vein Endothelial Cells
Aptitude
Kaposi's Sarcoma
Neoplasms
Cell Migration Inhibition
Neoplasm Metastasis
Gelatinases
Porifera
Chemotaxis
Sulfhydryl Compounds
Basement Membrane
Carcinogenesis
Phenotype
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Cai, T., Fassina, G., Morini, M., Aluigi, M. G., Masiello, L., Fontanini, G., ... Albini, A. (1999). N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Laboratory Investigation, 79(9), 1151-1159.

N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. / Cai, Tania; Fassina, GianFranco; Morini, Monica; Aluigi, Maria Grazia; Masiello, Luciana; Fontanini, Gabriella; D'Agostini, Francesco; De Flora, Silvio; Noonan, Douglas M.; Albini, Adriana.

In: Laboratory Investigation, Vol. 79, No. 9, 09.1999, p. 1151-1159.

Research output: Contribution to journalArticle

Cai, T, Fassina, G, Morini, M, Aluigi, MG, Masiello, L, Fontanini, G, D'Agostini, F, De Flora, S, Noonan, DM & Albini, A 1999, 'N-acetylcysteine inhibits endothelial cell invasion and angiogenesis', Laboratory Investigation, vol. 79, no. 9, pp. 1151-1159.
Cai T, Fassina G, Morini M, Aluigi MG, Masiello L, Fontanini G et al. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Laboratory Investigation. 1999 Sep;79(9):1151-1159.
Cai, Tania ; Fassina, GianFranco ; Morini, Monica ; Aluigi, Maria Grazia ; Masiello, Luciana ; Fontanini, Gabriella ; D'Agostini, Francesco ; De Flora, Silvio ; Noonan, Douglas M. ; Albini, Adriana. / N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. In: Laboratory Investigation. 1999 ; Vol. 79, No. 9. pp. 1151-1159.
@article{eabd3f53b2d047519ce26fd97491d575,
title = "N-acetylcysteine inhibits endothelial cell invasion and angiogenesis",
abstract = "The thiol N-acetylcysteine (NAC) is a chemopreventive agent that acts through a variety of mechanisms and can prevent in vivo carcinogenesis. We have previously shown that NAC inhibits invasion and metastasis of malignant cells as well as tumor take. Neovascularization is critical for tumor mass expansion and metastasis formation. We investigated whether a target of the anti-cancer activity of NAC could be the inhibition of the tumor angiogenesis-associated phenotype in vitro and in vivo using the potent angiogenic mixture of Kaposi's sarcoma cell products as a stimulus. Two endothelial (EAhy926 and human umbilical vein endothelial [HUVE]) cell lines were utilized in a panel of assays to test NAC ability in inhibiting chemotaxis, invasion, and gelatinolytic activity in vitro. NAC treatment of EAhy926 and HUVE cells in vitro dose-dependently reduced their ability to invade a reconstituted basement membrane, an indicator of endothelial cell activation. Invasion of HUVE cells was inhibited with an ID50 of 0.24 mM NAC, whereas inhibition of chemotaxis required a 10 fold higher doses, indicating that invasion is a preferential target. NAC inhibited the enzymatic activity and conversion to active forms of the gelatinase produced by endothelial cells. The matrigel in vivo assay was used for the evaluation of angiogenesis; NAC strongly inhibited neovascularization of the matrigel sponges in response to Kaposi's sarcoma cell products. NAC prevented angiogenesis while preserving endothelial cells, implying that it could be safely used as an anti-angiogenic treatment.",
author = "Tania Cai and GianFranco Fassina and Monica Morini and Aluigi, {Maria Grazia} and Luciana Masiello and Gabriella Fontanini and Francesco D'Agostini and {De Flora}, Silvio and Noonan, {Douglas M.} and Adriana Albini",
year = "1999",
month = "9",
language = "English",
volume = "79",
pages = "1151--1159",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - N-acetylcysteine inhibits endothelial cell invasion and angiogenesis

AU - Cai, Tania

AU - Fassina, GianFranco

AU - Morini, Monica

AU - Aluigi, Maria Grazia

AU - Masiello, Luciana

AU - Fontanini, Gabriella

AU - D'Agostini, Francesco

AU - De Flora, Silvio

AU - Noonan, Douglas M.

AU - Albini, Adriana

PY - 1999/9

Y1 - 1999/9

N2 - The thiol N-acetylcysteine (NAC) is a chemopreventive agent that acts through a variety of mechanisms and can prevent in vivo carcinogenesis. We have previously shown that NAC inhibits invasion and metastasis of malignant cells as well as tumor take. Neovascularization is critical for tumor mass expansion and metastasis formation. We investigated whether a target of the anti-cancer activity of NAC could be the inhibition of the tumor angiogenesis-associated phenotype in vitro and in vivo using the potent angiogenic mixture of Kaposi's sarcoma cell products as a stimulus. Two endothelial (EAhy926 and human umbilical vein endothelial [HUVE]) cell lines were utilized in a panel of assays to test NAC ability in inhibiting chemotaxis, invasion, and gelatinolytic activity in vitro. NAC treatment of EAhy926 and HUVE cells in vitro dose-dependently reduced their ability to invade a reconstituted basement membrane, an indicator of endothelial cell activation. Invasion of HUVE cells was inhibited with an ID50 of 0.24 mM NAC, whereas inhibition of chemotaxis required a 10 fold higher doses, indicating that invasion is a preferential target. NAC inhibited the enzymatic activity and conversion to active forms of the gelatinase produced by endothelial cells. The matrigel in vivo assay was used for the evaluation of angiogenesis; NAC strongly inhibited neovascularization of the matrigel sponges in response to Kaposi's sarcoma cell products. NAC prevented angiogenesis while preserving endothelial cells, implying that it could be safely used as an anti-angiogenic treatment.

AB - The thiol N-acetylcysteine (NAC) is a chemopreventive agent that acts through a variety of mechanisms and can prevent in vivo carcinogenesis. We have previously shown that NAC inhibits invasion and metastasis of malignant cells as well as tumor take. Neovascularization is critical for tumor mass expansion and metastasis formation. We investigated whether a target of the anti-cancer activity of NAC could be the inhibition of the tumor angiogenesis-associated phenotype in vitro and in vivo using the potent angiogenic mixture of Kaposi's sarcoma cell products as a stimulus. Two endothelial (EAhy926 and human umbilical vein endothelial [HUVE]) cell lines were utilized in a panel of assays to test NAC ability in inhibiting chemotaxis, invasion, and gelatinolytic activity in vitro. NAC treatment of EAhy926 and HUVE cells in vitro dose-dependently reduced their ability to invade a reconstituted basement membrane, an indicator of endothelial cell activation. Invasion of HUVE cells was inhibited with an ID50 of 0.24 mM NAC, whereas inhibition of chemotaxis required a 10 fold higher doses, indicating that invasion is a preferential target. NAC inhibited the enzymatic activity and conversion to active forms of the gelatinase produced by endothelial cells. The matrigel in vivo assay was used for the evaluation of angiogenesis; NAC strongly inhibited neovascularization of the matrigel sponges in response to Kaposi's sarcoma cell products. NAC prevented angiogenesis while preserving endothelial cells, implying that it could be safely used as an anti-angiogenic treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032845512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032845512&partnerID=8YFLogxK

M3 - Article

C2 - 10496534

AN - SCOPUS:0032845512

VL - 79

SP - 1151

EP - 1159

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 9

ER -